Company / Cash & Equivalents
Dianthus Therapeutics, Inc. /DE/ Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$51.1M
FY2025
5-year range
$15.4M / $132.3M
FY2021-FY2025
Trend
+124.1%
vs FY2024
Sector context
#181 of 207
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s cash & equivalents of $51M is lower than 87% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 9 years, ranging from $15M in FY2022 to $132M in FY2023.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of -2.6%.
Declined from $132M to $51M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +49.3%
- 5-Year CAGR
- -2.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 207This company $51.1M Sector average $669.5M
▼
-92.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 124.1% year-over-year.
- Ranks #181 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.1M | +124.1% |
| FY2024 | $22.8M | -82.8% |
| FY2023 | $132.3M | +761.2% |
| FY2022 | $15.4M | -88.3% |
| FY2021 | $131.7M | +126.4% |
| FY2020 | $58.2M | -10.6% |
| FY2019 | $65.1M | +11.5% |
| FY2018 | $58.3M | +13.5% |
| FY2017 | $51.4M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026